WG report backs: New TB Vaccines & TB/HIV INAT Meeting November 12, 2010 Berlin.

Slides:



Advertisements
Similar presentations
R&D Financing by the Bill & Melinda Gates Foundation
Advertisements

TB VACCINES: What’s New??
The Global Laboratory Initiative Assisting countries to implement the WHA resolution on MDR-TB Karin Weyer, WHO-STB, GLI secretariat John Ridderhof, CDC,
BCG and Other Candidate Vaccines for Tuberculosis RajKumar Kayal Guwahati.
Chapter Sixteen Science, Technology, and Global Health.
Working Group on New Vaccines. Purpose of the Working Group on New Vaccines Facilitate the development of new, more effective TB vaccine by promoting.
Tuberculosis Vaccines: A strategic blueprint for the next decade Co-editors: Michael J. Brennan and Jelle Thole.
Hope in the TB Pipeline II: Vaccines Peg Willingham Aeras Global TB Vaccine Foundation J2J Lung Health Media Training 41st Union World Conference on Lung.
Pediatric TB and HIV The Potential of New TB Vaccines
XDR-TB Francesco Blasi Department Pathophysiology and Transplantation,
Economic urgency and the pathway to eliminate TB Dr Mario Raviglione Director, Global TB Programme World Health Organization, Geneva, Switzerland Photo:
Prospects for the introduction of the HPV vaccine in developing countries and overcoming barriers of access Daisy Mafubelu Assistant Director General World.
Update on TB Vaccines Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town.
 Education:  General Practitioner - FK.UNHAS 1994  Pediatrician – FK.UNHAS 2003  Fellowship Pediatric respirologist FK-UI/RSCM  Diploma In Immunology.
Technical Advisory Group meeting, WHO/WPRO
EoI assesment and presentation NCP 24 October 2002 Confronting the major communicable diseases linked to poverty Health Directorate F3 unit: Poverty related.
The status of progress towards new TB vaccines Hassan Mahomed South African Tuberculosis Vaccine Initiative, University of Cape Town but also on behalf.
TB Vaccine Development Update 16 th Annual Conference of the Union North America Region New Tools Session 24 February 2012 Lew Barker, MD, MPH Aeras. Rockville,
TB vaccines: what is on the horizon? Tom Evans, MD Chief Scientific Officer, Aeras IAC, Washington, D.C., July 27, 2012.
Hope in the Pipeline The Search for New TB Vaccines Peg Willingham Aeras Global TB Vaccine Foundation “Journalist to Journalist” National Press Foundation.
Global Health Program Guiding Principles April 2002.
Xpert in the diagnostic algorithm of pulmonary TB in adult patients who are neither high risk for HIV, nor high risk for MDR-TB Preparations for the global.
HIV/AIDS Treatment and Care Clinical protocols for the WHO European Region 23 November 2007 World AIDS Day Jeffrey V. Lazarus WHO Europe, STI/HIV/AIDS.
Childhood TB Subgroup of the DEWG: update on policy recommendations Robert Gie Chairperson, Childhood TB Subgroup 31 October 2006 IUATLD Symposium: from.
Partnerships in TB Vaccine Research & Development
WHO Global Tuberculosis Control 2011 Report
Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb.
2005–2012 NIH Funding for Select Infectious Diseases (in Millions) * Includes ARRA stimulus funds National Institutes of Health (U.S.). Estimates of funding.
Hope in the TB Vaccine Pipeline Sebastian Gelderbloem Aeras Global TB Vaccine Foundation 25 January 2011.
Potential Cost-Effectiveness of a Tuberculosis Vaccine: Implications for Clinical Trials Jared Ditkowsky Kevin Schwartzman MD, MPH Montreal Chest Institute,
Update and future directions for prequalification of medicines WHO HQ, Geneva, 4 February 2008 Dr Lembit Rägo Coordinator Quality Assurance and Safety:
Approaches to TB Vaccine Development Peg Willingham Aeras Global TB Vaccine Foundation Beyond BCG: Towards an Effective New Vaccine for TB All Party Parliamentary.
TASK FORCE ON RETOOLING STOP TB PARTNERSHIP Cape Town November 2007.
WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.
Bridging Gap in Global Innovation – From need to Access, Said Business School, University of Oxford 9-13 September 2007 Strategies for Managing Innovation.
New initiatives for TB vaccines TBVAC Follow-up to the TB vaccine cluster, led by the Pasteur Institute Goal is to take the best new TB vaccines through.
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
Public-Private Partnerships -Selected Experiences in the Western Pacific & Cambodia- National Forum on Public-Private Partnership in Health 7 November,
INAT Communications Plan - Draft: a case study INAT Core Group Meeting Berlin November 12, 2010.
R&D for TB: Updates & Opportunities for the Private Sector Christian Lienhardt Senior Scientific Advisor, Stop TB Partnership WHO, Geneva GBC Conference.
1 |1 | Treatment 2.0 Catalyzing the Next Phase of Scale-up Gottfried Hirnschall Director, HIV Department WHO, Geneva.
Update of the Global Plan to Stop TB TB/HIV Working Group Meeting Geneva, November 2009 Christian Lienhardt.
End TB Strategy HCW with cough since January. Seen at government clinic thrice with no sputum/CXR. Diagnosed TB in May only.
INAT and Research Christian Lienhardt Stop TB Partnership Geneva First Meeting of the Core Group of the Subgroup on Introducing New Tools and Approaches.
Tuberculosis is a global public health issue. The Role of the International Agencies Introduction TB which stands for Tuberculosis is a rather infectious.
TB Control Measures: From development and endorsement to adoption and implementation Léopold Blanc TBS Stop TB department WHO Christy Garcia University.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
WHO EURO In Country Coordination and Strengthening National Interagency Coordinating Committees.
Global TB Research – as part of the new End TB Strategy Research Methods course McGill University – 6-10 July 2015 Dr Dick Menzies.
Meeting of the Working Group on TB Drug Development Why you need to be engaged? Marcos Espinal Executive Secretary Stop TB Partnership 29 October 2004.
Human clinical trial of DNA-MVA HIV vaccine candidate begins A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector.
Thorny Issues in HIV Vaccine Trials Saul Walker Policy Advisor IAVI.
TB HIV Research Perspectives of The Union Riitta Dlodlo, MD, MPH HIV Programme Coordinator The International Union Against Tuberculosis and Lung Disease.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
Page 0 UNITAID’s Strategic Approach to HIV Diagnostics  Washington DC 22 July, 2012 XIX International AIDS Conference Brenda Waning.
WHO Medicines Strategy Progress: Priorities: Dr Guitelle Baghdadi Essential Drugs and Medicines Policy World Health Organization November.
3rd WHO Prequalification Stakeholders Meeting :Diagnostics 3rd Stakeholders Meeting on Prequalification Geneva, 4th February 2008 Update on Prequalification.
LFA PSM expert workshop January 2014 Strategies for supporting the rational scale-up of laboratory monitoring of HIV.
Progress in TB Vaccine Development
Tuberculosis prevention
Tuberculosis prevention
Overview of vaccines prequalification
Demonstrate and Measure the Impact of the Application of the Principles of Medical Informatics in Low-Resource Settings Gerry Douglas, PhD Assistant Professor.
The STOP TB Working Group on Diagnostics
European & Developing Countries Clinical Trials Partnership (EDCTP)
World Health Organization
Tuberculosis and the President’s Emergency Plan for AIDS Relief
TB VACCINES WORKING GROUP
Highlights from the IAS TB/HIV 2019 symposium
5th edition NTP MANUAL OF PROCEDURES Chapter 1: Introduction
Presentation transcript:

WG report backs: New TB Vaccines & TB/HIV INAT Meeting November 12, 2010 Berlin

Goal and strategies for New TB Vaccines Safe and effective in preventing TB - including M/XDR- in children, adolescents and adults, including people with HIV Types of Vaccines –Preexposure –Postexposure (Current BCG vaccine strategy) –Immunotherapy Prime-Boost Strategy –Boost BCG or a recombinant BCG (rBCG) with a second, different vaccine designed to extend and enhance immune protection –Replace BCG with a recombinant BCG (rBCG) or attenuated live M.tb vaccine as the prime

TB Vaccine Pipeline VPM 1002 Max Planck, Vakzine Projekt Mgmt, TBVI rBCG30* UCLA, NIH, NIAID, Aeras AdAg85A McMaster University Hybrid-I+CAF01 SSI Hyvac 4/ AERAS-404 SSI, Sanofi-Pasteur, Aeras, Intercell RUTI Archivel Farma M smegmatis* Hybrid-I+IC31 SSI, TBVI, Intercell M72 GSK, Aeras MVA85A/ AERAS-485 Oxford-Emergent Tuberculosis Consortium (OETC), Aeras AERAS-402/ Crucell Ad35 Crucell, Aeras M vaccae* Immodulon, NIH Preclinical Phase IIPhase IIIPhase IIbPhase I *indicates candidates that have been in clinical trials in the past, but are not currently being tested in clinical trials Source: Tuberculosis Vaccine Candidates – 2009; Stop TB Partnership Working Group on New TB Vaccines As of November 2009 AERAS-422 Aeras Mtb [∆lysA ∆panCD ∆secA2] Albert Einstein College of Medicine MTBVAC01 [∆phoP, ∆fad D26] University of Zaragoza, Institute Pasteur, TuBerculosis Vaccine Initiative (TBVI) HBHA Institute Pasteur of Lille, INSERM, TBVI Hybrid 56 Statens Serum Institute (SSI), Aeras, Intercell, TBVI HG85 A/B Shanghai H&G Biotech Prime Boost Post-infection Immunotherapy Preclinical vaccine candidates are not yet in clinical trials, but have been manufactured under Good Manufacturing Practice (GMP) for clinical use and have undergone some preclinical testing that meets regulatory standards.

Facilitating access to New TB Vaccines Include new TB vaccines in EPI programs and extend the system to adolescent/adult vaccination Consider appropriate and innovative licensure procedures to accelerate access to market Strengthen health systems and identify innovative approaches to allow for mass vaccinations Find the “reasonable” balance between affordability, direct and indirect return on investment, societal benefits and sustainable production

Role for INAT? Can INAT play a role in clarifying the regulatory pathway? Help to clarify WHO mechanism (eg. STAG’s role in SAGE) and accelerate pre-qualification (can this process be done in conjunction with phase III studies) Assist in identifying what information is needed and by whom (eg. MOH, EPI and/or NTP) to make decisions about uptake of vaccines on country level

Current priorities of TB/HIV WG 3 I’s - IPT/ICF Guidelines Global Consultation on the implementation considerations for scale-up of Xpert MTB/RIF TB/HIV Collaborative Policy revision Focus on delivery of decentralized HIV services (eg. ART) in TB settings Ensuring linkages between diagnostic and care Systematize and regulate use of GeneXpert at PEPFAR sites

Role of INAT? Influence NACP and HIV service providers Need guidance from INAT on the role they can play for implementation WGs